Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis.
The formation of new blood vessels proceeds by both vasculogenesis and angiogenesis. The development of models, which fully recapitulate spatio-temporal events involved during these processes, are crucial to fully understand their mechanisms of regulation. In vitro differentiation of murine embryonic stem (ES) cells has been shown to be a useful tool to investigate factors and genes potentially involved in vasculogenesis (Hirashima et al, 1999; Risau et al, 1988; Vittet et al, 1996; Wang et al, 1992; Wartenberg et al, 1998). We asked here whether this model system can also recapitulate angiogenesis, which may offer new means to study mechanisms involved in this process. ES-derived embryoid bodies (EBs) obtained after 11 days of differentiation, in which a primitive vascular network had formed, were then subcultured into a type I collagen matrix. In the presence of angiogenic growth factors, EBs rapidly developed branching pseudopods. Whole mount immunostainings with a PECAM antibody revealed that more than 75% EBs displayed, within a few days, a large number of endothelial outgrowths that can give tube-like structures with concomitant differentiation of alpha-smooth muscle actin positive cells, thus evoking sprouting angiogenesis. High expression levels of flk1 (VEGFR2), flt1 (VEGFR1), tie-1, and tie-2 are also found, indicating that budding endothelial cells displayed an angiogenic phenotype. The endothelial sprouting response was specifically induced by angiogenic factors with a major contribution of vascular endothelial growth factor (VEGF). Known angiostatic agents, such as platelet factor 4 (PF4), angiostatin, and endostatin inhibited the formation of endothelial sprouts induced by angiogenic factors. Moreover, consistent with the in vivo phenotype, VE-cadherin deficient EBs failed to develop angiogenesis in this model. ES cell differentiation can then recapitulate, in addition to vasculogenesis, the early stages of sprouting angiogenesis. This model system, in which genetic modifications can be easily introduced, may be of particular interest to investigate unsolved questions and molecular mechanisms involved in blood vessel formation.
Feraud
O
O
Laboratoire de Transgenèse et Différenciation Cellulaire, CEA Grenoble, DBMS, Grenoble, France.
Cao
Y
Y
Vittet
D
D
D043168:Angiostatins; D000818:Animals; D015703:Antigens, CD; D015820:Cadherins / Q000502:physiology; D003094:Collagen / Q000494:pharmacology; D043170:Collagen Type XVIII; D004622:Embryo, Mammalian / Q000502:physiology*; D005314:Embryonic and Fetal Development; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000196:embryology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005782:Gels; D008222:Lymphokines / Q000494:pharmacology; D051379:Mice; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology; D010958:Plasminogen / Q000494:pharmacology; D010978:Platelet Factor 4 / Q000494:pharmacology; D013234:Stem Cells / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099152:Cadherin 5
D043168:Angiostatins; D015703:Antigens, CD; D015820:Cadherins; D003094:Collagen; D043170:Collagen Type XVIII; D043169:Endostatins; D016228:Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D005782:Gels; D008222:Lymphokines; D010446:Peptide Fragments; D010958:Plasminogen; D010978:Platelet Factor 4; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099152:Cadherin 5